MannKind forced to withdraw CEO job offer; Eisai's Lenvima wins European fast-track designation;

@FiercePharma: BioAtla scores $45M investment for CAB development. FiercePharmaAsia story | Follow @FiercePharma

@CarlyHFierce: ICYMI: U.K. investor Woodford calls again for breakup of 'complicated' GSK. Article | Follow @CarlyHFierce

> After being dumped by marketing partner Sanofi ($SNY) on inhaled insulin Afrezza, MannKind ($MNKD) says it was forced to withdraw a job offer to a new CEO. Report

> Eisai's Lenvima has been fast-tracked in Europe for use as a treatment for metastatic renal cell carcinoma. More

> A federal appeals court has affirmed a district court's ruling that a patent covering Purdue's sleep disorder drug Intermezzo (zolpidem tartrate) was invalid for obviousness. More

> Horizon Pharma ($HZNP) has raised its 2016 sales outlook thanks to the expected close of its Crealta Holdings buy later this week. More

> Cost regulators for the National Health Service in Scotland have approved funding for 6 new therapies, Bayer's Nexavar among them. More

Medical Device News

@FierceMedDev: Medtronic to build Chinese facility for the manufacture of advanced diabetes devices. Article | Follow @FierceMedDev

@EmilyWFierce: Congressional reps urge the NIH to 'march in' on rising drug prices. FiercePharma story | Follow @EmilyWFierce

@VarunSaxena2:  | Follow @VarunSaxena2

> JPM: Illumina's genomic ambitions fueled by new sequencing tools and technology. Story

> Boston Scientific launches disposable digital urinary tract endoscope. Article

> JPM: Medtronic aims for double-digit returns with more buybacks, faster dividends and debt paydown. More

Biotech News

@FierceBiotech: Juno buys into sequencing; Moderna cozies up to Big Pharma; and more from . Article | Follow @FierceBiotech

@JohnCFierce: Sounds right. Deal fest in San Francisco while takes an ugly 5% drop. Bon chance to you stock guys; off to a rough start at . | Follow @JohnCFierce

@DamianFierce: warm memories from last year's jp morgan when, after a full day of meetings, I found this on the back of my collar. More | Follow @DamianFierce

> Much-hyped Moderna barrels into the clinic with 6 human trials planned for '16. Report

> Merck buys out IOmet, adding new immuno-oncology tech. Article

Drug Delivery News

> Australia's Elastagen receives $9M to deploy its human protein formulation to aesthetics and tissue repair. News

> Back-of-the-eye delivery outfit Clearside files for $58 million IPO. Story

> One microcapsule could combine two drug ingredients when triggered at tumor site. More

> JPM: Halozyme to focus on its internal pancreatic cancer candidate in 2016. Report

> Xeris raises $41M to develop diabetes injection pen for glucagon administration. Article

Pharma Manufacturing News

> BD exiting sterile injectables biz, selling plant and portfolio to Fresenius Kabi. More

> Consent decree issued against recalcitrant compounder. Item

> Perrigo, already recalling Zyrtec copy, now recalling knockoff of Mucinex for children. Report

> FDA warning letter tells Cadila to resolve problems with warfarin production. Story

> European regulators sanction Chinese company for plant flaws. Article

Pharma Asia News

> BioAtla scores $45M investment for CAB development. More

> Japan's Takeda and enGene in GI therapy development pact. Item

> Glenmark's BEAT platform helps develop new cancer molecule. Article

> Amgen sues South Korea's Samsung Bioepis over Enbrel biosimilar. Report

> Singapore's NRF unveils 5-year, $13B research budget. Story

And Finally... People who take proton pump inhibitors for heartburn may be more likely to develop chronic kidney disease than individuals who don't, according to a new study. More

Suggested Articles

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.